Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 13
Tirzepatide and MASLD: a mouse study
A mouse study ties tirzepatide's liver effect in MASLD to the CCL2/CCR2 axis, adding mechanistic detail to SYNERGY-NASH.
Tirzepatide in Smith-Magenis syndrome
A JCEM case report found 9.4% weight loss and reduced aggression in a patient with Smith-Magenis syndrome on tirzepatide 5 mg weekly.
Tirzepatide after bariatric surgery
An Italian study reports 18.1% weight loss at 24 weeks in 34 post-bariatric patients on tirzepatide. Early data, small sample.
GLP-1 constipation: prevalence vs incidence
A 2026 study argues many GLP-1 users had constipation before starting treatment, inflating the headline rate.
GLP-1 drugs and fewer knee replacements
A database study of over 42,000 patients links GLP-1 receptor agonist use to significantly lower rates of knee replacement surgery.
Semaglutide lifts lymphatic pump in mice
A 2026 mouse study found GLP-1 receptors concentrated in lymphatic endothelial cells. Semaglutide activation improved vessel pumping capacity.
SURPASS-CVOT and the GLP-1 ceiling question
A JACC commentary asks why tirzepatide beat dulaglutide on metabolism but not on MACE in SURPASS-CVOT, and what GIP receptor activation adds beyond GLP-1.
Tirzepatide CV biomarkers in SURMOUNT-1
A SURMOUNT-1 post hoc analysis found tirzepatide reduced CRP, IL-6, leptin, and PAI-1 at 72 weeks. What the biomarker shifts mean, and what they do not.
15-PGDH and muscle loss on GLP-1 drugs
A Stanford mouse study finds that inhibiting 15-PGDH preserved muscle repair during semaglutide weight loss without reducing fat loss.
GLP-1 and GIP drugs in fat cells
A 2026 review maps what GLP-1 and dual GIP/GLP-1 agonists do inside human adipocytes, and finds most evidence still comes from rodent models.
Tirzepatide and Lithium Toxicity: A Case
A case report ties tirzepatide to lithium toxicity severe enough for hemodialysis. What GLP-1 patients on lithium should know.
Anti-dementia drugs in 2026: what works
A German review covers old-line dementia drugs, new amyloid antibodies, and why semaglutide failed in two large Alzheimer's trials.